Ultragenyx Pharmaceutical... (RARE)
35.37
1.53 (4.52%)
At close: Apr 02, 2025, 3:59 PM
34.29
-3.05%
After-hours: Apr 02, 2025, 05:11 PM EDT
Ultragenyx Pharmaceutical Balance Sheet Statement
| Year | FY24 | FY23 | FY22 | FY21 | FY20 | FY19 | FY18 | FY17 | FY16 | FY15 | FY14 | FY13 | FY12 | FY11 |
| Cash & Equivalents | 173.73M | 213.58M | 132.94M | 307.58M | 713.53M | 433.58M | 113.43M | 100.49M | 161.12M | 93.57M | 24.32M | 7.43M | 86.19M | 10.64M |
| Short-Term Investments | 436.3M | 363.63M | 614.82M | 432.61M | 488.01M | 321.65M | 346.27M | 134M | 219.03M | 343.43M | 163.16M | 45.95M | n/a | n/a |
| Long-Term Investments | n/a | 199.9M | 154.5M | 293.86M | 165.88M | 32.93M | 1.82M | 9.97M | 117.96M | 99.26M | n/a | n/a | n/a | n/a |
| Other Long-Term Assets | 197.68M | 57.69M | 10.7M | 11.62M | -24.54M | -4.19M | 3.51M | 3.41M | -92.5M | 2.73M | 7.45M | 3.1M | 509K | 417K |
| Receivables | 121.8M | 73.39M | 40.45M | 28.43M | 23.09M | 32.84M | 12.74M | 5.17M | n/a | n/a | n/a | n/a | n/a | 103K |
| Inventory | 45.01M | 33.97M | 26.77M | 16.23M | 13.05M | 11.55M | 7.07M | 757K | n/a | n/a | n/a | n/a | n/a | n/a |
| Other Current Assets | 40.29M | 47.62M | 68.93M | n/a | n/a | n/a | n/a | n/a | 1.41M | 150K | 5.93M | 1.85M | n/a | n/a |
| Total Current Assets | 817.12M | 732.18M | 883.9M | 856.6M | 1.3B | 851.02M | 522.37M | 244.47M | 498.11M | 450.21M | 187.49M | 55.23M | 86.44M | 10.95M |
| Property-Plant & Equipment | 265.93M | 290.57M | 285.69M | 176.18M | 114.04M | 74.68M | 20.05M | 21.84M | 17.05M | 7.37M | 3.03M | 1.32M | 1.36M | 759K |
| Goodwill & Intangibles | 222.72M | 210.68M | 204.51M | 175.19M | 175.52M | 173.41M | 173.63M | 185.95M | n/a | n/a | n/a | n/a | n/a | n/a |
| Total Long-Term Assets | 686.33M | 758.83M | 661.54M | 665.79M | 464.25M | 284.48M | 197.19M | 246.28M | 42.52M | 109.36M | 10.48M | 4.42M | 1.87M | 1.18M |
| Total Assets | 1.5B | 1.49B | 1.55B | 1.52B | 1.76B | 1.14B | 719.56M | 490.75M | 540.63M | 559.57M | 197.97M | 59.65M | 88.32M | 12.13M |
| Account Payables | 38.76M | 42.11M | 43.27M | 17.14M | 12.92M | 12.87M | 12.28M | 8.89M | 5.36M | 2.94M | 4.86M | 1.44M | 1.2M | 342K |
| Deferred Revenue | n/a | n/a | 1.48M | 7.61M | 59.22M | n/a | n/a | 5.99M | n/a | n/a | n/a | n/a | n/a | n/a |
| Short-Term Debt | 10.3M | n/a | 11.78M | 11.07M | 8.98M | 7.24M | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| Other Current Liabilities | 295.1M | 142.79M | 113.96M | 71.9M | 82.68M | 34.63M | n/a | n/a | 37.67M | 15.55M | 85K | 78K | 75K | n/a |
| Total Current Liabilities | 344.15M | 280.44M | 261.21M | 181.37M | 189.61M | 103.3M | 74.72M | 71.01M | 60.26M | 27.92M | 12.52M | 5.92M | 3.19M | 999K |
| Long-Term Debt | n/a | n/a | n/a | 351.79M | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| Other Long-Term Liabilities | 866.95M | 904.59M | 880.26M | 1M | 335.67M | 315.37M | 4.76M | 5.12M | 6.39M | 561K | 505K | 3.62M | 788K | 487K |
| Total Long-Term Liabilities | 897.01M | 935.16M | 931.74M | 418.47M | 415.57M | 378.43M | 35.92M | 36.28M | 6.39M | 561K | 505K | 3.62M | 788K | 487K |
| Total Liabilities | 1.24B | 1.22B | 1.19B | 599.84M | 605.18M | 481.73M | 110.65M | 107.3M | 66.65M | 28.48M | 13.02M | 9.54M | 3.98M | 1.49M |
| Total Debt | 10.3M | 43.17M | 31.59M | 41.97M | 48.23M | 36.99M | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| Common Stock | 92K | 82K | 70K | 69K | 67K | 58K | 51K | 44K | 41K | 39K | 32K | 4K | 3K | 3K |
| Retained Earnings | -3.96B | -3.39B | -2.78B | -2.07B | -1.62B | -1.43B | -1.03B | -832.67M | -530.53M | -284.66M | -139.04M | -74.84M | -27.06M | -8.15M |
| Comprehensive Income | -643K | 647K | -6.57M | -1.4M | 689K | -147K | -633K | -5.68M | 905K | -868K | -174K | 11K | -353K | -40K |
| Shareholders Equity | 255.3M | 275.41M | 352.49M | 922.56M | 1.15B | 653.76M | 608.91M | 383.45M | 473.97M | 531.09M | 184.94M | 50.11M | 84.34M | 10.64M |
| Total Investments | 436.3M | 563.53M | 620.35M | 726.47M | 653.89M | 354.57M | 346.27M | 143.98M | 336.99M | 442.69M | 163.16M | 45.95M | n/a | n/a |